LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)

The OBLITERATE trial is studying whether targeted local treatments (such as radiation or ablation) given to a small number of progressing tumors in the lungs or chest can extend the benefit of ongoing systemic cancer treatment. It focuses on lung cancers — both non-small cell and small cell — that are mostly under control but have a few newly growing spots. **You may be eligible if...** - You are 18 or older - You have confirmed non-small cell or small cell lung cancer - You are currently on systemic therapy (e.g., chemotherapy, immunotherapy) with mostly stable disease - You have 5 or fewer spots of cancer that are newly growing or progressing - Those progressing spots can be safely treated with radiation or ablation - You have had at least 1 prior line of systemic therapy with at least 3 months of benefit **You may NOT be eligible if...** - Your health conditions prevent safe local ablative therapy - Prior treatment side effects rule out ablative procedures - You have cancer growing in the brain Talk to your doctor to see if this trial is right for you.